GL Pharmtech, Aju Pharmaceuticals' 'Latica Eye Drops' Approved as Korea's 44th New Drug
Promotes Mucus Secretion to Improve Corneal and Conjunctival Epithelial Disorders
Swift Approval Enabled by Dedicated Product Team at the Ministry of Food and Drug Safety
The Ministry of Food and Drug Safety announced on September 8 that it has approved 'Latica Eye Drops 5% (Rekoflavone Hydrate)' from Aju Pharmaceuticals as Korea's 44th new drug.
This medication was co-developed by Aju Pharmaceuticals and GL Pharmtech. It is used to treat adults with dry eye disease by promoting mucus secretion on the ocular surface to improve corneal and conjunctival epithelial disorders. The Ministry of Food and Drug Safety expects that this will provide patients with dry eye disease a broader range of treatment options.
Latica Eye Drops 5% was approved in accordance with the 'New Drug Product Approval and Review Work Procedures' guideline established by the Ministry of Food and Drug Safety last year. The approval process involved the formation of a dedicated product team including 20 expert reviewers, priority review for clinical trials (GCP) and manufacturing and quality management (GMP), and customized face-to-face meetings before and after the product approval application. This close communication with the company enabled a swift approval process.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
The Ministry of Food and Drug Safety stated, "We will continue to enhance the predictability, transparency, and speed of the approval and review process so that safe and effective medicines can be delivered promptly to patients."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.